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Abstract
Background: To reduce the burden of asthma, chronic disease management (CDM) programmes have been widely
implemented and evaluated. Reviews including randomised controlled trials (RCTs) suggest that CDM programmes
for asthma are effective. Other study designs are however often used for pragmatic reasons, but excluded from
these reviews because of their design. We aimed to examine what complementary information could be retrieved
from the addition of non-randomised studies to the studies included in a published Cochrane review on asthma
CDM programmes, for healthcare stakeholders involved in the development, implementation, conduct or long-term
sustainability of such programmes.
Methods: Extending a previously published Cochrane review, we performed a systematic review (augmented
review) including any type of study designs instead of only those initially accepted by Cochrane and the Effective
Practice and Organization of Care Review group. After double data selection and extraction, we compared study
and intervention characteristics, assessed methodological quality and ran meta-analyses, by study design.
Results: We added 37 studies to the 20 studies included in the Cochrane review. The applicability of results was
increased because of the larger variety of settings and asthma population considered. Also, adding non-randomised
studies provided new evidence of improvements associated with CDM intervention (i.e. healthcare utilisation, days
off work, use of action plan). Finally, evidence of CDM effectiveness in the added studies was consistent with the
Cochrane review in terms of direction of effects.
Conclusions: The evidence of this augmented review is applicable to a broader set of patients and settings than
those in the original Cochrane review. It also strengthens the message that CDM programmes have a beneficial
effect on quality of life and disease severity, meaningful outcomes for the everyday life of patients with asthma.
Despite the moderate to low methodological quality of all studies included, calling for caution in results
interpretation and improvements in CDM evaluation methods and reporting, the inclusion of a broader set of study
designs in systematic reviews of complex interventions, such as chronic disease management, is likely to be of high
value and interest to patients, policymakers and other healthcare stakeholders.
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Background
Asthma is a global health problem affecting over 300
million people worldwide [1] and a major cause of dis-
ability, poor quality of life, health resources utilisation,
and costs [2–4]. Despite the availability of effective ther-
apies, asthma control remains suboptimal, calling for the
implementation and evaluation of effective asthma man-
agement interventions [5]. These include chronic disease
management (CDM) programmes, which are more than
simple patient education, encompassing a set of coher-
ent interventions that centres on the patients’ needs, fo-
cuses on education and self-management, on healthcare
integration and coordination provided by various profes-
sionals, as well as on improvements in communication
between patients and healthcare providers [6–12].
Summarising the evidence of CDM programmes for
asthma in a systematic review is not an easy task [13].
Most often, state-of-the art Cochrane systematic reviews
of interventions include randomised controlled trials
(RCTs) only [14]. However, RCTs are often not the most
suitable design for evaluating complex and context-
dependent interventions [15–17]. Non-randomised stud-
ies, such as controlled and uncontrolled before-after
studies, are often undertaken in the pragmatic context
of CDM programme implementation in communities
[16]. These non-randomised studies could be very in-
formative for the various healthcare stakeholders in-
volved in the development, implementation, conduct
and long-term sustainability of such programmes, espe-
cially in terms of contexts, key components and imple-
mentation processes. Including non-randomised studies
(NRS) or non-controlled studies (NCS) in systematic re-
views is challenging, however, notably when assessing
study quality and the potential for selection bias and its
impact on study results [14, 18]. Yet, reviews and meta-
reviews have shown that non-randomised studies do not
systematically lead to biased results and that there is
little evidence for significant effect estimate differences
between observational studies and RCTs [14, 19].
The main objective of this systematic review was to
examine what complementary information could be re-
trieved from the addition of NRS and NCS to a published
Cochrane review on asthma CDM programmes, for
healthcare stakeholders involved at various levels in the
development, implementation, conduct and long-term
sustainability of such programmes. We also assessed how
the effectiveness of asthma CDM programmes varied
across included study designs.
Methods
This systematic review (augmented review throughout the
text) is an extension of a previously published Cochrane re-
view [20] evaluating the effectiveness of CDM programmes
in adults with asthma, that was conducted independently
from Cochrane. We used the same methodology as in the
Cochrane review, except for study designs considered, risk
of bias assessments and some aspects of the statistical ana-
lyses. While major methodological elements are presented
thereafter, details of the methodology of the published
Cochrane review are available in the original text [20].
Identification of studies and eligible study design
In the original review, we searched the following data-
bases: MEDLINE, EMBASE, CINHAL, PSYCINFO, CEN-
TRAL Cochrane and the Specialized Registers of the
Effective Practice and Organisation of Care (EPOC) and
Airways Disease Groups up to June 2014 [20]. We also
hand-searched reference lists of retrieved papers and
relevant narrative or systematic reviews, and registers of
clinical trials to identify new and ongoing trials. Language
restrictions were not applied. Eligible study designs in the
original review were RCTs, quasi-randomised controlled
trials (QRCTs) (i.e. an experimental study in which partici-
pants are prospectively allocated using a method that is
not random), controlled before-after studies (CBA*s) (i.e.
a study in which observations are made before and after
the implementation of an intervention, both in a group
that receives an intervention and in a control group that
does not, with at least two intervention and two control
sites) and interrupted time series (ITS*s) (i.e. a study that
uses observations at multiple time points before and after
an intervention, with at least three data points available
before and after the intervention), complying with the
guidelines from the EPOC Review group [21]. In this aug-
mented review, we did not run a new search but modified
the design inclusion criteria to also include any CBAs, any
ITSs, before-after studies without an external control
group (BAs) (i.e. outcomes are measured before and after
the implementation of an intervention, in a single group)
and cross-sectional studies (XSs) (i.e. concurrent measure-
ment of intervention and outcomes), identified in the ori-
ginal search of the Cochrane review and excluded because
of the study design (n = 66). We excluded studies present-
ing secondary analyses and implementation results only.
Types of interventions and outcomes
We included CDM programmes targeting adult partici-
pants with a diagnosis of asthma in both reviews, if the
following five criteria were all met: 1) at least one organ-
isational component targeting patients; 2) at least one or-
ganisational component targeting healthcare professionals
and/or the healthcare system; 3) presence of patient edu-
cation and/or self-management support component; 4) ac-
tive involvement of two or more healthcare professionals
in the patient’s care; 5) minimum duration of 3 months of
at least one of the criteria one to three.
In both reviews we looked at the same organisational
and patient-level outcomes; the ten primary outcomes,
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pre-defined in the Cochrane protocol [20], were also
considered in this augmented review. Organisational
outcomes included organisation of care outcomes, process
outcomes (use of an action plan), and healthcare use
outcomes (hospitalisations, unscheduled visits to an emer-
gency department or physician office). Patient-level out-
comes included quality of life (QoL) outcomes (asthma-
specific QoL), symptoms and activity level outcomes
(asthma severity, asthma exacerbations, days off work/
school), self-care outcomes (self-efficacy scores), lung
function outcomes (forced expiratory volume in one sec-
ond (FEV1) or peak expiratory flow rate (PEFR)), and
patient satisfaction.
Data extraction
Two reviewers, working independently and in duplicate,
re-assessed the previously excluded articles (n = 66) for
eligibility criteria and extracted data regarding study de-
sign, country and healthcare setting, CDM intervention
(number of and main component, comprehensiveness of
intervention -eight or more components-, duration of
the longest component), patient characteristics (age, sex,
asthma severity) and reported outcomes (structure indica-
tors, process of care and intermediate measures, clinical
effect). Where required, we sought additional information
by contacting authors.
Assessment of risk of bias
We assessed the methodological quality of the studies
using the Cochrane Collaboration’s tool modified by
EPOC [22] for assessing risk of bias for RCTs, QRCTs,
and CBAs, used in the original review, with additional
items for BAs, ITSs and XSs extracted from various
instruments: the new Cochrane risk of bias assessment
tool for non-randomised studies of interventions
(ACROBAT-NRSI) [23], the checklist for the assessment
of the methodological quality of both randomised and
non-randomised studies of health care interventions by
Downs and Black [24], and the quality assessment tool
for quantitative studies by the Effective Public Health
Practice Project (EPHPP) [25, 26]. Domains of bias in-
cluded in the final instrument, selected by consensus
among authors to discriminate the quality of all study
designs and encompass all relevant bias domains, were
1) random sequence generation, 2) allocation conceal-
ment, 3) baseline characteristics similar, 4) baseline out-
comes similar, 5) confounding unlikely, 6) appropriate
analyses (e.g. adjusted or time trend analyses if required),
7) sample representative of source population, 8) inter-
vention independent of other changes, 9) intervention
integrity (e.g. intervention delivered as intended and
consistently, adequate protection against contamination),
10) blinding of outcome assessment, 11) incomplete
outcome data addressed, and 12) free of other bias (see
Additional file 1 for the risk of bias extraction form).
Any disagreement was resolved by discussion or involve-
ment of an arbitrator, or both.
Measures of treatment effect and data synthesis
Measures of treatment effect were reported separately by
study design, as suggested by recent guidance on includ-
ing NRS in systematic reviews [27]. For RCTs, we re-
ported results of dichotomous outcomes as odd ratios
(OR) and results of continuous outcomes as mean differ-
ences (MD) or standardized mean differences (SMD) if
different instruments or scales were used for a scale-type
outcome, using post intervention (follow-up) values.
SMDs were calculated by dividing the difference in mean
scores between the intervention and control group by an
estimate of the (pooled) standard deviation, resulting in
a ‘scale free’ estimate of the effect for each study which
can be pooled across studies regardless of the scale of
measurement used in each study. Using rules of thumb,
SMDs lower than 0.4 represent a small effect, SMDs
between 0.4 and 0.7 represent a moderate effect, and
SMDs higher than 0.7 represent a large effect [28]. For
QRCTs, CBA*s, and CBAs, we intended to report results
derived from statistical analyses adjusting for baseline
measures. However, as adjusted results were not avail-
able in the included studies, we reported OR, MD or
SMD using follow-up values only. CBA*s and CBAs
were analysed in the same study design group. For XSs,
we also reported unadjusted OR, MD and SMD as ad-
justed results were not available. For BAs, we reported
OR and MD or SMD, considering the baseline data as
data for the “control” group. For ITSs, we planned to
compare time trends before and after the intervention,
or to re-analyse the data if analyses in the original paper
were inappropriate, according to EPOC guidance [29].
However, because of the lack of reported data in the
ITSs, re-analysis was not possible and we considered
ITS data as BA data.
We reported the number of times the ten primary
outcomes were assessed, and the number of times that
statistically significant results favouring CDM were
found by authors (for at least one dimension in case of
scale outcomes), by study design. Then, where possible,
we conducted meta-analyses using the Cochrane Review
Manager software [30] to calculate the overall effect size
for all relevant outcomes. We pooled results of studies
of similar design using the random-effects model [21] to
incorporate some level of expected heterogeneity among
pooled studies. All results were expressed with 95 %
confidence intervals, and statistical heterogeneity among
trials was examined with Cochran’s Q test and by calculat-
ing the I2 statistic describing the proportion of variability
in the summary estimate that is due to heterogeneity ra-
ther than by chance.
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Results
Of the 10,593 records identified in the Cochrane re-
view, 20 studies (from 27 articles) met all inclusion
criteria and 66 articles were excluded because of the
study design. Of these 66 excluded articles, 29 were
rejected because no outcomes were available, children
represented more than 50 % of the sample, or the
intervention did not fulfil the inclusion criteria after
further examination, leading to 37 remaining articles
to additionally consider in the augmented review. Ten
other articles were found by hand searching the reference
lists of included articles. We therefore included 27
Cochrane articles and 47 additional articles, for a total of
57 studies, from 74 articles, in this augmented review (see
flow diagram in Fig. 1 and key components of all included
studies in the supplementary table (see Additional file 2)).
These 57 studies consisted of seven CBAs [31–37], 22 BAs
[38–59], six ITSs [60–65] and two XSs [66, 67], in addition
to the 15 RCTs [68–82], one QRCT [83, 84], and four
CBA*s [85–88] of the Cochrane review.
Characteristics of included studies
Programme and recruitment setting
Details of the 57 studies are presented in Table 1 and in the
supplementary table (see Additional file 2: Supplementary
Table). While about half of the RCTs and CBA*s in the
Cochrane review were carried out in North America (USA
and Canada), only 30 % of the studies added in this aug-
mented review were held in that region. These studies were
carried out more often in Europe (Finland, Germany,
Netherlands, Russia, Spain, Sweden, Switzerland, UK) and
other parts of the world (Australia, Brazil, India, New
Zealand, Thailand) compared to the countries represented
in the RCTs, QRCT and CBA*s (Denmark, France,
Germany, Netherlands, UK and Australia, Japan, Taiwan).
Also, they recruited patients from a larger variety of
patient pools: five studies recruited patients from the
general population compared to none in the Cochrane
studies and a higher percentage of studies recruited
patients in specialised clinics or outpatient hospital
departments. Finally, care was delivered proportionally
more often in specialised clinics or outpatient hospital
departments in the studies added in this augmented re-
view, compared to studies in the Cochrane review, which
were mostly community-based.
Study population
A total of 158,907 patients (between 25 and 70,900 per
study, median: 111) were included in the 51 studies
reporting this information, with a mean number of pa-
tients included in the studies that differed according to
study design (see Table 1): RCTs included less patients
on average compared to the other designs, while all ITSs
included over 10,000 patients. Patients’ mean age ranged
from 34.0 in the CBA*s to 48.5 in the XS reporting this
information, and the mean percentage of women in-
cluded in the studies ranged from 53 % in the CBA*s to
72 % in the CBAs. Compared with patients in RCTs,
those included in BAs appeared to suffer from less se-
vere asthma: the percentage of studies including patients
suffering from mild to moderate asthma was higher in
studies reporting this information, the mean FEV1 was
higher, and the mean percentage of patients using in-
haled corticosteroids (ICS) was lower.
Interventions
The mean number of independent components per CDM
intervention was highest in the ITSs, which were also
more often defined as comprehensive interventions
(including at least eight components), while BAs included
Fig. 1 Flow diagram. CDM: chronic disease management
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Table 1 Study and intervention characteristics, by study design
Studies in Cochrane review Newly added studies
RCT QRCT CBA* CBA BA ITS XS
N = 15 N = 1 N = 4 N = 7 N = 22 N = 6 N = 2
Study characteristics:
Publication year, mean (SD) 2004.0 (5.3) 2001 2004.8 (4.1) 2003.9 (6.1) 2002.8 (5.7) 2009.8 (4.0) 2006.5 (6.4)
Region, n (%)
Europe 4 (26.7 %) Denmark 1 (25.0 %) 0 9 (40.9 %) 3 (50.0 %) Sweden
North America 8 (53.3 %) - 2 (50.0 %) 4 (57.1 %) 6 (27.3 %) 1 (16.7 %) 0
Other 3 (20.0 %) - 1 (25.0 %) 3 (42.9 %) 7 (31.8 %) 2 (33.3 %) Brazil
Location of care, n (%)
Outpatient carea 3 (20.0 %) - 0 2 (28.6 %) 9 (40.9 %) 3 (50.0 %) 0
Community-based careb 6 (40.0 %) 1 3 (75.0 %) 3 (42.9 %) 10 (45.5 %) 1(16.7 %) 2 (100 %)
Mixed 6 (40.0 %) - 1 (25.0 %) 2 (28.6 %) 3 (13.6 %) 2 (33.3 %) 0
Recruitment pool, n (%)
General population 0 - 0 0 2 (9.1 %) 3 (50.0 %) 1 (50 %)
Insurance clients 2 (13.3 %) - 3 (75.0 %) 2 (28.6 %) 1 (4.5 %) 1 (16.7 %) 0
PCP/Pharmacy 5 (33.3 %) 1 1 (25.0 %) 2 (28.6 %) 7 (31.8 %) 0 1 (50 %)
Outpatientsc 3 (20.0 %) - 0 2 (28.6 %) 8 (36.3 %) 2 (33.3) 0
Inpatients 3 (20.0 %) - 0 0 0 0 0
Multisector 2 (13.3 %) - 0 1 (14.3 %) 4 (18.2 %) 0 0
Patients, mean (SD) 157.7 (153.1) 413 19742 (34137.3) 683.0 (1157.5) 347.4 (725.2) 32553 (16363.9) 330.5 (24.7)
Median 96 - 3717 239.5 100.0 32553 330.5
Age, mean (SD) 43.0 (6.3) 40.6 34.0 (3.6) 42.3 (5.4) 42.2 (6.8) nr 48.5
Women, mean % (SD) 61.3 (14.7) 56.2 % 52.8 (10.6) 71.8 (4.5) 66.6 (11.1) nr 55.5 (2.3)
Asthma severity, n (%)
Mild-moderate 1 (6.7 %) - 0 0 7 (31.8 %) 0 1 (50 %)
Moderate-severe 11 (73.3 %) 1 0 4 (57.1 %) 10 (45.5 %) 0 0
Not reported 3 (20.0 %) - 4 (100.0 %) 3 (42.9 %) 5 (22.7 %) 6 (100 %) 1 (50 %)
FEV1, mean (SD) 64.6 (20.9) nr nr nr 79.4 (10.4) nr nr
ICS use, mean % (SD) 73.8 (32.0) nr nr 74.4 (26.5) 52.0 (30.3) 52.8 (36.4) 44.7 %
Intervention characteristics:
Number of intervention components,
mean (SD)
8.5 (2.5) 9 7.8 (2.5) 7.1 (1.2) 6.7 (2.0) 10.0 (2.1) 7
Comprehensive intervention
(≥8 components), n (%)
8 (53.3 %) 1 2 (50.0 %) 3 (42.9 %) 5 (22.7 %) 5 (71.4 %) 0
Main component, n (%)
Educational 7 (46.7 %) - 1 (25.0 %) 6 (85.7 %) 14(63.6 %) 0 1 (50 %)
Org_healthcare 2 (13.3 %) - 2 (50.0 %) 1 (14.3 % 6 (27.3 %) 5 (71.4 %) 1 (50 %)
Org_patient 1 (6.7 %) 1 0 0 0 0 0
Multicomponent 5 (33.3 %) - 1 (25.0 %) 0 2 (9.1 %) 1 (16.7 %) 0
Duration of intervention (months), mean (SD) 7.5 (3.2) 12 22.5 (21.0) 12.5 (12.6) 13.1 (8.0) ongoing 4
RCT randomised controlled trial, QRCT quasi-randomised controlled trial, CBA* controlled before-after study (with at least two intervention and two control sites),
CBA controlled before-after study, ITS interrupted-times-series study, BA before-after study (without external control group), XS cross-sectional study (with concurrent
measurement of intervention exposure and outcomes), PCP primary care practice, SD standard deviation, FEV1 forced expiratory volume in 1 s (% predicted), ICS inhaled
corticosteroids, Org organisational, nr not reported
aOutpatient care: ambulatory care provided by specialised clinic or hospital
bCommunity-based care: care provided at a primary care practice, pharmacy or health unit
cOutpatients: patients seen by specialised clinic or outpatient hospital department
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fewer components and were less often comprehensive (see
Table 1). Education and/or self-management support was
the main component in most CBAs and BAs, while the
RCTs were more often multi-component. The three com-
ponents most often implemented in RCTs were individual
education sessions (100 % of RCTs), explicit teamwork and
collaborative processes between healthcare providers (87 %
of RCTs) and structured follow-up (80 % of RCTs),
while the three most frequent components in the
QRCT and CBA*s were individual education sessions
(80 % of studies), structured follow-up (80 % of studies),
reminders, feedback and other routine reporting sheets
(80 % of studies). In studies added in this augmented re-
view, the three most frequent components were struc-
tured follow-up (68 % of studies), healthcare professionals
education (68 % of studies) and providing an action plan
(62 % of studies). The RCTs evaluated shorter interven-
tions on average (mean duration less than 12 months)
compared to the other designs. Thirteen of the newly
added studies were ongoing (without time limitation),
while none of the studies in the Cochrane review was
ongoing.
Fig. 2 Risk of bias by study design. Low risk of bias; Unclear risk of bias; High risk of bias; Not applicable; RCT: randomised
controlled trial; QRCT: quasi-randomised controlled trial; CBA*: controlled before-after study (with at least two intervention and two control
sites); CBA: controlled before-after study; ITS: interrupted-times-series study; BA: before-after study (without external control group); XS:
cross-sectional study (with concurrent measurement of intervention exposure and outcomes)
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Outcome measures
A large variety of outcomes were reported in the studies
(all reported outcomes are listed in the supplementary
table (see Additional file 2: Supplementary Table)). While
RCTs reported more often self-reported scale outcomes
(i.e. score on asthma-specific QoL, asthma severity, asthma
knowledge and self-care), the studies added in this
augmented review reported more often healthcare use and
days off work/school. In addition, while the four outcomes
most often measured in RCTs were asthma-specific quality
of life (80 % of RCTs), medication use and ICS prescription
(60 % of RCTs), hospitalisations (53 % of RCTs) and
asthma severity (53 % of RCTs), the four outcomes most
often reported in the QRCT and CBA*s were hospitalisa-
tions (all five studies), unscheduled visits (60 % of studies),
general practitioner visits (60 % of studies) and ICS
prescription (60 % of studies). In the studies added in this
augmented review, the four outcomes most often reported
were hospitalisations (in 65 % of studies), unscheduled
visits (62 % of studies), ICS prescription (38 % of studies)
and delivery of intervention (38 % of studies).
Risk of bias
In the Cochrane review, the quality of the evidence was
rated as moderate to low based on the GRADE approach
[89] , despite the fact that most studies were RCTs. This
was mainly due to study design limitations, which re-
sulted in either unclear or high risk of bias in most cases
and in wide confidence intervals. Detail assessment can
be found in the Cochrane publication [20] and in Fig. 2.
In this augmented review, the overall methodological
quality of the newly added studies was rated as low (see
Fig. 2 for risk of bias assessment per study). More specific-
ally, only two of the seven CBAs attempted to minimize
confounding bias by stratifying patients according to
asthma severity [31] and matching the control group for
age, gender, onset of asthma, healthcare use, and employ-
ment [34]. Also, across all designs, most studies were at
high risk of confounding bias and did not run appropriate
analyses. For instance, only two ITSs performed appro-
priate trend analyses, using the Cochran Armitage test for
trend [64] and linear regression modelling [65]. In ad-
dition, patients were deemed representative of the source
population (i.e. included patients comprising the entire
source population, an unselected sample of consecutive
patients or a random sample) in less than half of the in-
cluded studies and most studies were at unclear risk of
bias regarding the independence of the intervention from
other changes. Lastly, while more than half of the studies
were at high risk of detection bias (outcomes not assessed
blindly), about half of the studies were at low risk of
attrition bias (less than 20 % of patients lost to follow-up)
and most studies were at low risk of intervention integrity
(interventions delivered as intended and consistently).
Effects of asthma CDM programmes
We report in the following section the effectiveness re-
sults for the pre-defined ten primary outcomes.
Among the 57 included studies of this augmented re-
view, 17 studies did not contribute to any meta-analysis,
because of data format heterogeneity (e.g. continuous
versus dichotomous data, change from baseline versus
follow-up data only) and data unavailability.
Overview
Table 2 displays the number of studies reporting statisti-
cally significant effects associated with CDM for the nine
primary outcomes (no data was found for asthma exac-
erbations, one of the primary outcomes), among studies
reporting the outcome of interest, by study design.
Across all outcomes, the RCTs, QRCT and CBA*s of the
Cochrane review had lower proportion of outcomes that
Table 2 Study effects, by study design
Number of studies reporting SS effect / number
of studies reporting outcome
Studies in Cochrane review Newly added studies
RCT QRCT CBA* CBA BA ITS XS
N = 15 N = 1 N = 4 N = 7 N = 22 N = 6 N = 2
Asthma-specific quality of life 9 / 12 1 / 1 1 / 1 2 / 3 5 / 5 - -
Hospitalisations 3 / 6 0 / 1 0 / 2 3 / 4 8 / 13 3 / 6 0 / 1
ED or unscheduled visits 1 / 6 0 / 1 0 / 2 3 / 4 13 / 16 1 / 2 1 / 1
Asthma self-efficacy 4 / 5 - 1 / 1 2 / 2 3 / 3 - 1 / 1
Asthma severity 5 / 8 1 / 1 - 2 / 2 6 / 7 1 / 1 1 / 1
Days off school or work 0 / 2 - 0 / 1 0 / 1 8 / 11 - -
Use of an action plan 1 / 2 - 2 / 2 3 / 3 4 / 5 1 / 2 1 / 1
Patient satisfaction 0 / 2 0 / 1 - - 2 / 3 0 / 1 -
Lung function 4 / 12 0 / 1 - 1 / 1 6 / 13 - -
RCT randomised controlled trial, QRCT quasi-randomised controlled trial, CBA* controlled before-after study (with at least two intervention and two control sites),
CBA controlled before-after study, ITS interrupted-times-series study, BA before-after study (without external control group), XS cross-sectional study (with concurrent
measurement of intervention exposure and outcomes), SS statistically significant, ED emergency department
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significantly improved in response to CDM (49.1, 33.3
and 44.4 %, respectively) compared to CBAs, BAs, ITSs
and XSs (80.0, 72.4, 50.0 and 80.0 %, respectively).
Across all designs, outcomes that significantly improved
more often were asthma self-efficacy (91.7 %), asthma-
specific QoL (81.8 %), asthma severity (80.0 %) and use
of an action plan (80.0 %), while outcomes that im-
proved less often were patient satisfaction (28.6 %), lung
function (40.7 %), days off work or school (53.3 %) and
healthcare use (hospitalisation 51.6 %, unscheduled visit
59.4 %). We present below the meta-analysis results (if
available) for the ten primary outcomes, by order of a
priori defined clinical significance.
Asthma-specific quality of life
CDM programmes resulted in improved asthma-specific
QoL scores in all designs, with a small effect in RCTs
(SMD 0.22, 95 % CI 0.08 to 0.37, 8 studies), moderate
effect in BAs (SMD 0.44, 95 % CI 0.16 to 0.72, 4 studies)
and the QRCT (SMD 0.46, 95 % CI 0.27 to 0.66, 1
study), and large effect in CBAs (SMD 0.79, 95 % CI
0.25 to 1.34, 2 studies) (Fig. 3).
Healthcare use: hospitalisations and unscheduled visits
While we were not able to perform meta-analysis on
healthcare use data in the Cochrane review because of
the wide variability in means and rates at baseline,
Fig. 3 Asthma-specific quality of life score, forest plot by study design. RCT: randomised controlled trial; QRCT: quasi-randomised controlled trial;
CBA: controlled before-after study; BA: before-after study (without external control group); INT: intervention; CON: control; SD: standard deviation;
IV: inverse variance; CI: confidence interval
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length of follow-up, data type and reasons for healthcare
use (asthma-specific or all-cause), we were able in this
augmented review to run meta-analyses on the percent-
age of patients with one or more hospitalisation and one
or more unscheduled visits (Fig. 4). Only the meta-
analyses for the BAs showed a significant lower likeli-
hood of hospitalisation and unscheduled visit at follow-
up compared to baseline (OR 0.41, 95 % CI 0.23 to 0.72,
8 studies and OR 0.45, 95 % CI 0.28 to 0.72, 7 studies,
respectively).
Asthma exacerbations
Meta-analysis on asthma exacerbations, defined as
prompting hospitalisation, an unscheduled or ED visit,
or systemic rescue glucocorticoids, was not possible as
data were not reported as such in the included studies.
Self-efficacy
CDM programmes were associated with improvement in
asthma self-efficacy scores, with a moderate, incon-
clusive and heterogeneous effect in RCTs (SMD 0.51,
Fig. 4 Percentage patients with ≥1 hospitalisation and ≥1 unscheduled visit, forest plot by study design. RCT: randomised controlled trial; BA:
before-after study (without external control group); XS: cross-sectional study (with concurrent measurement of intervention exposure and
outcomes); INT: intervention; CON: control; M-H: Mantel-Haenszel; CI: confidence interval
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95 % CI −0.08 to 1.11, 5 studies, I2 = 91 %), a moderate
effect in CBAs (SMD 0.56, 95 % CI 0.23 to 0.89, 2 studies)
and a large effect in the BA (SMD 0.88, 95 % CI 0.62
to 1.13, 1 study) (Fig. 5).
Asthma severity
Asthma severity scores improved in all designs, with a
small effect in RCTs (SMD 0.18, 95 % CI 0.05 to 0.30, 6
studies) and in the BA (SMD 0.35, 95 % CI 0.10 to 0.60,
1 study), a moderate effect in the QRCT (SMD 0.47,
95 % CI 0.27 to 0.66, 1 study), and large effect in the
CBAs (SMD 1.04, 95 % CI 0.66 to 1.42, 2 studies)
(Fig. 6).
Days off work or school
While we were not able to pool data on days off work or
school in the Cochrane review because of their heteroge-
neous format, we were able to pool BAs reporting the
percentage of patients who missed at least one day of
work or school due to asthma; it showed a moderate
reduction after the intervention (OR 0.45, 95 % CI 0.29
to 0.71, 8 studies) (Fig. 7).
Use of an action plan
The pooled OR for the percentage of patients with an
action plan at follow-up ranged from 2.41 (95 % CI 1.56
to 3.73) for the XS, 2.99 (95 % CI 2.39 to 3.75) for
the eight BAs with a high degree of heterogeneity
(I2 = 87 %), 3.50 (95 % CI 0.83 to 14.85) for the RCT, to
4.99 (2.64 to 9.42) for the three CBAs (Fig. 8).
Patient satisfaction
Due to the heterogeneity of patient satisfaction measures,
we were unable to perform meta-analysis on patient
satisfaction.
Lung function
CDM programmes were associated with improvement in
lung function (FEV1 or PEF value reported as per cent
of predicted value or L/min) in all designs, with a small
effect in all designs (SMD 0.19, 95 % CI 0.09 to 0.30 in
eight RCTs, SMD 0.26, 95 % CI 0.06 to 0.45 in the
QRCT, SMD 0.30, 95 % CI 0.18 to 0.42 in eight BAs)
(Fig. 9).
Secondary outcomes
By adding NRS and NCS, we were able to examine one
secondary outcome and run two additional meta-analyses
on two secondary outcomes reported in sufficient
studies to allow comment and analysis in the following
paragraphs.
Fig. 5 Self-efficacy score, forest plot by study design. RCT: randomised controlled trial; CBA: controlled before-after study; BA: before-after study
(without external control group); INT: intervention; CON: control; SD: standard deviation; IV: inverse variance; CI: confidence interval
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Fig. 6 Asthma severity score, forest plot by study design. RCT: randomised controlled trial; QRCT: quasi randomised controlled trial; CBA:
controlled before-after study; BA: before-after study (without external control group); INT: intervention; CON: control; SD: standard deviation;
IV: inverse variance; CI: confidence interval
Fig. 7 Percentage patients who missed≥1 day off work or school, forest plot by study design. BA: before-after study (without external control
group); INT: intervention; CON: control; M-H: Mantel-Haenszel; CI: confidence interval
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The impact of CDM programmes on the frequency of
GP visits was bi-directional. One RCT found less fre-
quent GP visits in the intervention group compared to
the control group [78], while one QRCT [83] and one
CBA [87] found more frequent GP visits. Two BAs
found more frequent GP visits per patient at follow-up
compared to baseline [44, 45], while five BAs and one
ITS found on the contrary that the number of GP visits
par patient decreased in the intervention group com-
pared to baseline [39–42, 47, 61].
The pooled SMD for asthma knowledge ranged from
0.53 (95 % CI 0.03 to 1.02) for the CBA, 0.83 (95 % CI
0.63 to 1.03) for the QRCT, 1.08 (95 % CI 0.16 to 2.0)
for six RCTs with a high degree of heterogeneity (I2 =
97 %), to 2.25 (95 % CI −0.44 to 4.93) for three BAs with
a high degree of heterogeneity as well (I2 = 99 %)
(Fig. 10).
The pooled SMD for medication compliance scores
ranged from 0.24 (95 % CI −0.01 to 0.50) for three RCTs,
0.57 (95 % CI −0.13 to 1.26) for two BAs with a high
Fig. 8 Percentage patients with an action plan, forest plot by study design. RCT: randomised controlled trial; CBA: controlled before-after study;
BA: before-after study (without external control group); XS: cross-sectional study (with concurrent measurement of intervention exposure and
outcomes); INT: intervention; CON: control; M-H: Mantel-Haenszel; CI: confidence interval
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degree of heterogeneity (I2 = 83 %), to 0.77 (95 % CI
0.32 to 1.22) for the CBA (Fig. 11).
Discussion
Including study designs other than RCTs, QRCTs and
CBA*s allowed the addition of 37 studies to the 20 studies
included in the Cochrane review. In terms of study and
intervention characteristics, the newly added studies
allowed the consideration of programmes taking place in
proportionally more countries outside of North America
that included population-wide interventions with greater
number of patients in a greater variety of settings and
patient pools, and were of longer duration. In addition,
patients in the studies of this augmented review suffered
from less severe asthma. In terms of effectiveness, results
from the meta-analyses confirmed that CDM programmes
were significantly favourable to patients. Indeed, they im-
proved asthma-specific QoL, asthma severity scores and
lung function across all designs, with the size of effect
varying by study design: CBAs and BAs showing more
often larger effects than RCTs. CDM interventions also
significantly improved self-efficacy scores in CBAs and
BAs, while the meta-analysis was inconclusive in RCTs. In
addition, we were able to perform meta-analysis of health-
care use in this augmented review, which was not possible
in the Cochrane review: while RCTs did not show signifi-
cant improvement for healthcare use outcomes, BAs
showed lower likelihood of hospitalisations and unsched-
uled visits after CDM interventions. Finally, the augmen-
ted review permitted the consideration of additional
outcomes: CDM interventions were associated with de-
creased likelihood of patients missing days off work or
Fig. 9 Lung function (FEV1 or PEF, in % predicted value or L/min), forest plot by study design. RCT: randomised controlled trial; QRCT: quasi
randomised controlled trial; BA: before-after study (without external control group); INT: intervention; CON: control; SD: standard deviation; IV:
inverse variance; CI: confidence interval
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school in BAs, and increased likelihood of using an action
plan in BAs, CBAs, and one XS.
Adding NRS and NCS to the original Cochrane review
increased the applicability of the Cochrane evidence, as
the variety of settings and profile of patients in the newly
added studies represent probably better the general set-
ting and target patient population of most asthma CDM
programmes. Previous studies have already reported that
patient populations selected for recruitment in RCTs in
the respiratory field, and more specifically in asthma,
represent only about 5 % of the patient population being
treated by clinicians in everyday practice [90]. Although
RCTs are important and necessary to establish the effi-
cacy of new therapies and interventions, their usefulness
can be limited when evaluating how complex inte-
rventions will perform in routine care in the real world
[91, 92]. In fact, new guidance on conducting systematic
reviews of effectiveness interventions encourages the in-
clusion of non-RCTs to allow for in-depth descriptions
of study components and the context and process of
implementing the intervention [93]. A few years after
that publication, a meta-review of study design criteria
in systematic reviews of health systems interventions
positively showed that only one third of reviews re-
stricted study designs to RCTs [94].
Overall, evidence from all study designs was consistent
in terms of the direction of the effect; because of the in-
creased applicability, such results strengthen the conclu-
sion of the Cochrane review that CDM programmes
have a positive effect on quality of life and asthma sever-
ity, meaningful outcomes for the everyday life of patients
with asthma. Adding non-randomised studies also allowed
us to run new meta-analyses showing improvements asso-
ciated with CDM programmes for five outcomes (hospi-
talisations, unscheduled visits, days off work, self-efficacy
and action plan) that could not be performed in the
Cochrane review. Despite the increased risk of bias, the
results, which align with the hypothesized trends, suggest
evidence of reduction of hospitalisations, unscheduled
visits and days off work. Such results are encouraging in
Fig. 10 Asthma knowledge score, forest plot by study design. RCT: randomised controlled trial; QRCT: quasi randomised controlled trial; CBA:
controlled before-after study; BA: before-after study (without external control group); INT: intervention; CON: control; SD: standard deviation;
IV: inverse variance; CI: confidence interval
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the context of healthcare spending reductions. According
to Schünemann and colleagues’ terminology [95], the NRS
and NCS evidence can be considered as complementary
(i.e. NRS and NCS provide additional information on
whether the intervention works in different populations)
and sequential (i.e. information not (yet) obtained or avail-
able from RCTs).
When looking at the effect sizes of RCT, NRS and
NCS, the proportion of outcomes reported by authors as
improved in response to CDM was higher in the newly
added studies compared with the studies in the
Cochrane systematic review. The newly added studies
(NRS and NCS) also showed both larger effect size than
RCTs and larger confidence intervals, indicating uncer-
tainty for the results in addition to high statistical het-
erogeneity. These results fuel the ongoing debate about
the impact of study design and associated biases on
study effect size. A number of reviews have been con-
ducted comparing effect sizes and biases of RCTs with
non-randomised studies and non-controlled studies.
While some reviews found that lack of randomisation or
inadequate randomisation was associated with selection
bias, larger effects, smaller effects, or reversed direction
of effects [14, 19, 96, 97], others found little to no differ-
ence in effect sizes between study designs or according
to study quality [98, 99]. As suggested by Rockers and
colleagues, non-experiments can produce valid and causal
effect estimates, in settings that are more natural than
RCTs [92]. More research is clearly needed on the issue of
study design, risk of bias assessment and effect size. A
special emphasis should be put on sound methods for
measuring and dealing with confounding bias in NRS
studies and other biases in NCS, as well as valid methods
for pooling NRS and NCS [100, 101].
Overall, randomised, non-randomised and non-
controlled studies included in this augmented review were
of moderate to low quality with regards to reporting, statis-
tical and methodology standards. While risk of presenting
uncertain results without knowing the direction or magni-
tude of the effect holds true for both non-randomised and
randomised controlled trials, risk of bias and confounding
is probably higher in non-randomised trials [97]. However,
a study at high risk of bias does not necessarily mean the
study results are actually biased. In the case of asthma
CMD programmes, other authors conducting similar sys-
tematic reviews have reported similar low quality of studies
[102, 103]. One reason for this low quality may be the lack
of widely accepted methods for evaluating CDM pro-
grammes, which are typical complex interventions, built
up from a number of interacting components, aiming to
modify both providers and patients behaviours, targeting
multiple organisational levels and groups, including a large
Fig. 11 Compliance with medication score, forest plot by study design. RCT: randomised controlled trial; CBA: controlled before-after study;
BA: before-after study (without external control group); INT: intervention; CON: control; SD: standard deviation; IV: inverse variance; CI: confidence
interval
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number and variety of outcomes and allowing a cer-
tain degree of flexibility (i.e. intervention tailored to
patients) [93]. Such complex interventions are difficult
to evaluate [104, 105], emphasizing the need for
sound evaluation methods to evaluate routine practice
in actual settings [106]. Recent guidance has been
published to help authors in developing and evaluat-
ing complex interventions in general [93, 107] and
CDM in particular [106, 108]. Guidelines to improve
the completeness and precisions of reporting inter-
ventions and their effectiveness have also been pub-
lished for a variety of study designs, such as the
template for intervention description and replication
(TIDieR) [109], SQUIRE 2.0 for quality improvement
studies [110], the CONSORT statement for RCTs [111],
and STROBE for cohort, case–control and cross-sectional
studies [112]. Future CDM evaluations should follow
these available guidelines to produce high-quality evi-
dence that can then be synthesized in systematic
reviews.
The main limitation of this review is that the initial
search of the Cochrane review was restricted to quanti-
tative studies, not including all types of available evi-
dence on CDM programmes, such as evidence from
implementation, qualitative and mixed methods research
which could lead to a more comprehensive understand-
ing of complex interventions.
Conclusions
Evidence from NRS and NCS complemented RCT evi-
dence from the Cochrane review. In fact, adding NRS
and NCS to the original Cochrane review both increased
the directness of the evidence, as the variety of settings
and profile of patients in the newly added studies prob-
ably better represent the general setting and target pa-
tient population of typical asthma CDM programmes,
and also strengthened the message that CDM pro-
grammes have a positive effect on quality of life and
asthma severity, which are meaningful outcomes for the
everyday life of patients with asthma. The inclusion of
study designs other than RCTs in systematic reviews
investigating the effectiveness of healthcare interven-
tions, especially when they are complex, is increasingly
considered to allow for in-depth descriptions of study
components and the context and process of imple-
menting the intervention [93, 94, 97]. However, while
NRS and NCS studies provide results from interven-
tions in real-life settings that may be valuable to patients,
healthcare providers, managers and policymakers, among
others, the methodological quality of the studies re-
mains suboptimal, calling for caution in effectiveness
results’ interpretation, as well as for improvements in
CDM evaluation methods and reporting by health
researchers.
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